Bone response to biosilicates® with different crystal phases by AZENHA, Marcelo Rodrigues et al.
Braz Dent J 21(5) 2010
Bone response to Biosilicate® 383
INTRODUCTION
Glasses and ceramics are routinely used in 
medical and dental treatments as bone substitutes, and 
their use has been greatly improved in the last 30 years 
(1,2). Biomaterials such as silicate, ceramics and calcium 
silicate glasses have been used aiming to improve bone 
repair and promote hard tissue substitution. These 
materials are able to interact with body tissue stimulating 
osteogenesis favoring undifferentiated mesenchymal 
cells mitogenesis, leading to osteoblast and new bone 
formation. Bioglass®45S5 and Biosilicate® demonstrated 
similar bioactivity and biocompatibility with significant 
increase of matrices of mineralized bone compared to 
a ceramic material (3). When bioglass implants are 
used in vivo, its osteocondutivity promotes deposition 
of a calcium-phosphate layer surrounding the implant, 
thus leading to osseointegration due to the interaction 
of the biomaterial in physiological environment 
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through biodissolution/biodegradation, apatite crystal 
precipitation, and bone formation around implant (4,5).
Ideally, a glass-ceramic system for substitution 
and bone augmentation should be osteoconductive and 
have reasonable mechanical properties (6), such as 
Bioglass®45S5, known as the material with the highest 
bioactivity index (7). Recently, a 100% crystallized 
glass-ceramic based on the general formula SiO2.
P2O5.Na2OCaO was developed and named Biosilicate® 
(Patented 0300644-1; Federal University of São Carlos, 
Brazil). Its crystallinity significantly changes the fracture 
characteristics of the glass. Roriz et al. (8) analyzing 
alveolar defects filled by Biosilicate® demonstrated that 
this material presents higher amount of mineralized tissue 
on its surface compared to the control group, suggesting 
that Biosilicate® has excellent biocompatibility and 
satisfactory mechanical properties. These results 
stimulate the development of new materials, such as 
bioactive glass to be used as scaffolds. The aim of this 
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study was to evaluate bone response and quantify the 
bone-to-implant contact (BIC) of three different crystal 
phases of Biosilicate® implants comparing them to 
Bioglass®45S5, used as control material. 
MATERIAL AND METHODS
This study was approved by the Ethics Committee 
for Animal Research of Ribeirão Preto Dental School, 
University of São Paulo, Brazil (Protocol- 07.1.975.53.0).
Sixteen 3-month-old New Zealand male rabbits 
weighting between 2.5 and 3.0 kg were used in the study 
with two implants placed bilaterally in the femur of each 
animal (64 implants). Bioglass®45S5 implants, based on 
the SiO2.CaO.Na2O.P2O5 composition were used as a 
control material due to their high efficiency in surface 
bone formation (2).
Sample Preparation and Surface Characterization 
Materials were prepared as previously described 
(9,10). Briefly, the Biosilicate® materials based 
on the general formula SiO2.P2O5.Na2O.CaO, and 
Bioglass®45S5 were obtained after weighing and mixing 
in rubber bottles high pure silica, calcium carbonate, 
sodium carbonate, and sodium phosphate during 30 
min. Materials fusion took place between 1250 and 
1380ºC after 3 to 4 h in an electric furnace (Rapid Temp 
1710BL; CM Furnaces Inc., Bloomfield, NJ, USA) at the 
Vitreous Material Laboratory of the Federal University 
of São Carlos, São Carlos, SP, Brazil and the Vitrovita 
– Instituto de Inovação em Vitrocerâmicos Ltda, São 
Carlos, SP, Brazil. Implants (2 x 4 mm2) were produced 
using the lost-wax casting technique. Plastic profiles 
of 2 x 4 mm2 were invested in a refractory material 
(Whip-mix gypsum bonded investment, Whipmix Corp., 
Louisville, NY, USA), which once set was heated to 
700ºC to burnout the plastic profile. The investment 
was then cooled to 590ºC prior to casting. The glass was 
melted at 1200ºC using an electrical furnace and then 
centrifugally cast into the investment mould (Degussa 
TS3 casting machine, Hanau, Germany). After grit blast 
the glass surface with 50 µm alumina, the rods were 
heat treated for 1 h at 520ºC and 1 h at 860ºC. These 
two different thermal treatments are essential to favor 
an initial crystallization at first cycle, and total material 
crystallization at a higher temperature. Biosilicate® 
composition and the thermal treatment protocol are 
detailed described at EP1601623B1 patent (Brazil). A 
very well domain on kinetic crystallization, nucleation, 
and growth allowed obtaining two glass ceramics fully 
crystallized: first showing only one crystalline phase 
containing 1Na2O.2CaO.3SiO2 and P2O5 in solid solution 
(named F1), and the second having two crystalline phases 
containing 1Na2O.2CaO.3SiO2 and a calcium phosphate 
phase (named F2).
The cast rods of glass measuring 2.2 x 4.0 mm 
(Fig. 1) were examined at the time of processing for 
defects such as porosity. Any specimen showing signs 
of porosity was discarded. Samples were immersed in 
acetone to remove any debris and abundantly irrigated 
with saline before implantation.
Implantation Procedures and Sample Harvesting
Each animal was submitted to bilateral femur 
surgery at same session with two implants being inserted 
in each femur (Fig. 2) (2). Fenaren (sodium diclofenac 
- 2 mg/kg) and Tramal (tramadol chloride - 1 mg/kg) 
Figure 1. Glass implants used in the study measuring 2.2 x 4.0 mm. 
Figure 2. Femur exposed with two implants inserted after bone 
perforation.
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were administered immediately and 24 h after surgery. 
The animals were maintained in cages with free access 
to food and water, and the wounds were inspected 
daily for clinical signs of complications or adverse 
reactions, and to monitor healing. At 8 and 12 weeks 
after implantation the animals were euthanized with 
a lethal dose of sodium thiopental. The femurs were 
harvested, radiographed to define implant location, and 
processed for morphological and histomorphometrical 
analyses. The periods of harvesting were selected based 
on previous studies (2,11,12).
Histological Processing 
The bone segments containing the implants were 
ground sectioned for light microscopy (13). The bone and 
implants were immediately fixed in 3% glutaraldehyde 
buffered with 0.1 M sodium cacodylate (pH 7.3) for 3 h. 
After fixation, the specimens were dehydrated through a 
series of graded ethanol solutions and embedded in resin 
(LH White Hard Grade, London, UK) over a period up 
to 9 days. Each specimen was placed in a polyethylene 
cup and filled with fresh resin, which was polymerized 
in an oven at 60ºC for 18 h. After polymerization, resin 
blocks were sectioned with a diamond knife (Microslice 
2; Ultratec Manufacturing Inc., Santa Ana, CA). The 
samples were polished using silicon carbide paper 
and diamond polishing pastes, and the polished block 
surfaces were stained and processed
 
with Stevenel’s 
blue and Alizarin red for light microscopy. The stained 
blocks were mounted on slides using glass bond and 
were cut using a diamond band saw to leave a section 
near 1 mm thick. The cut surfaces of the sections were 
polished and thinned down to 30-40 μm using silicon 
carbide paper without disruption of the implant tissue 
interface. Cover slips were used to protect the sections 
and the slides were examined under a standard light 
microscope.
The biocompatibility of the materials was based 
on their osseointegration and osteoconductivity capacity. 
For that, the length of the cross-sections of the samples 
was measured followed by measurement of the length 
of this perimeter in close contact with bone matrix 
at ×10 original magnification. BIC was expressed as 
percentage of the implant surface in direct contact with 
the mineralized bone matrix in the cortical and medullary 
areas. At least 6 slides per period of each material were 
used. This parameter was determined by using public 
domain image analysis software NIH Image (National 
Institutes of Health, Bethesda, MD, USA). 
Statistical Analysis
The data were subjected to the ANOVA and 
Tukey’s test using the SPSS/WIN statistical analysis 
program (SPSS Inc., Chicago, IL, USA). Differences at 
p≤ 0.05 were considered statistically significant.
RESULTS 
Clinical Observations
No intraoperative or postoperative complications 
were observed with the animals. The implantation 
sites appeared to have healed with no visible signs of 
inflammation or adverse tissue reaction. Radiographs 
confirmed that the implants had been placed successfully 
through cortex and maintained in femur marrow. 
Histological and Histomorphometrical Analyses
Histological evaluation demonstrated non-
absorbable cylinders localized at implantation sites with 
no persistent inflammation or foreign body reaction (Fig. 
3). In all experimental groups the bone healing resulted 
in the formation of lamellar bone trabeculae adjacent to 
or in direct contact with the implant surface (Fig. 4A-F). 
Considering the medullary area, Biosilicate® implants 
presented a close relationship with new bone formation, 
Figure 3. Histological aspect of Bioglass®45S5 implant into 
rabbit femur 8 weeks after surgical procedure (C, cortical bone, 
I, implant, M, medullary bone) (original magnification ×1.6).
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Figure 4. Ground sections of Biosilicate® cylinders after 8 and 12 weeks of implantation. A= Biosilicate®vítreo implant-tissue interface 
showing the cortical bone in close contact to the implant surface after 8 weeks; B= Biosilicate 1F - tissue interface showing bone 
formation between implant surface and the cortical bone at 8 weeks; C= Direct contact between the Bioglass®45S5 implant surface 
and cortical bone (12 weeks); D= Biosilicate 2F - direct contact at cortical region after 12 weeks; E= Implant - tissue interface showing 
bone formation in the medullary canal after 12 weeks (Biosilicate 2F); F= Bioglass®45S5 - arrow showing bone in close contact with 
the implant, in the medullary canal after 12 weeks; G= Bioglass®45S5 - tissue interface showing soft tissue in close contact with 
the implant, in the medullary canal after 8 weeks; H= Arrow showing soft tissue in close contact with Biosilicate 2F implant in the 
medullary canal after 12 weeks. b: cortical bone; i: implant; m: bone marrow; f: fibrous tissue. Original magnification: ×10.
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demonstrating the biocompatibility and osteocondutivity 
of tested materials (Figs. 4E and 4F). A layer of soft tissue 
was observed in close contact to implant surfaces in the 
medullary canal. The connective tissue was composed of 
a few elongated cells and collagen fibers located parallel 
to implant surface (Figs. 4G, 4H - arrows). The mean 
percentages of BIC at medullary and cortical regions 
are summarized in Tables 1 and 2.
The BIC in bone marrow at 8 weeks was 
as follows: Biosilicate®vitreo > Bioglass®45S5 > 
Biosilicate 2F > Biosilicate 1F. BIC at 12 weeks presented 
Biosilicate 1F > Biosilicate 2F > Biosilicate®vítreo > 
Bioglass®45S5. No significant difference was found 
between the materials or tested periods (p=0.08 and 
p=0.14 respectively). Considering BIC at cortical portion 
after 8 weeks, Biosilicate 2F presented the highest bone 
formation followed by Biosilicate 1F, Bioglass®45S5, 
and Biosilicate®vítreo. Biosiliacate1F and 2F presented 
similar results with no significant difference (p=0.06). 
However, in this period, Biosilicate 1F and 2F 
demonstrated higher BIC compared to Bioglass®45S5 
and Biosilicate®vítreo (p=0.02). At 12 weeks the BIC was 
similar between all tested materials without significant 
difference (p=0.08).
DISCUSSION
The results of the present study showed 
an excellent biocompatibility of Bioglass®45S5, 
Biosilicate®vitreo, Biosilicate 1F, and Biosilicate 2F 
after bone implantation. It is important to emphasize 
that Bioglass®45S5 has shown high bioactivity for 
many years (7). Different studies have reported that 
the Biosilicate® glass exerts more osteogenic activity 
than Bioglass®45S5 under subjective histopathological 
analysis (8,14). Accordingly, our results showed higher 
bioactivity of Biosilicate 1F and 2F at the cortical 
portion after 8 weeks. The results after twelve weeks 
confirmed similar behavior among Bioglass®45S5 and 
all tested Biosilicate® glass ceramics. It is important 
to emphasize that the percentage of osseointegration 
of Biosilicate 2F was 100% after 12 weeks and that 
Biosilicate 1F osseointegration process was finished 
after 8 weeks. In contrast to cortical portion, the BIC 
in bone marrow showed no statistically significant 
differences among tested materials. 
Our results suggest that new bone formation 
around the materials is influenced by their location 
within the bone, whether in the cortical bone as in 
the marrow bone. The osteogenic potential of the 
fibrous connective tissue at the bone marrow could be 
attributed to the migration of osteogenic cells from the 
endosteum during tissue repair. However, fragments 
of endosteum stripped off during surgical procedure 
that adhered to material surface could be the source of 
osteoblastic cells (2). Landry et al. (15) explain that 
activating periosteal or endosteal cells, as well as cells 
involved in the medullary repair system promotes an 
intense osteogenic response. This occurs at the initial 
repair phase, promoting new medullary bone formation. 
In this study, considering that all the samples were 
prepared under the same conditions, the implant surface 
topography was likely similar for all rods. Therefore, 
the BIC could not have been influenced by factors 
other than surface chemistry. Moura et al. (3) showed 
that full crystallization of bioactive glasses from P2O5.
Table 1. Bone-to-implant contact (BIC) of Biosilicate® samples 
and Bioglass®45S5 at the cortical area. 
Material 8 weeks 12 weeks
Bioglass®45S5 87(±8)a 92(±8)a,b
Biosilicate®vítreo 84(±15)a 92(±4)a,b
Biosilicate 1F 93(±6)b 90(±9)a,b
Biosilicate 2F 96(±4)b 100(±0)a,b
BIC is expressed as percentage of the implant surface in direct 
contact with the mineralized bone matrix in cortical and medullary 
area. Parentheses numbers represent the standard deviation. 
Number of samples of each tested biomaterial in each period 
of time (n=8). Different letters in columns indicate statistically 
significant difference (ANOVA and Tukey’s post hoc test).
Table 2. Bone-to-implant contact (BIC) of Biosilicate® samples 
and Bioglass®45S5 at the medullary area.
Material 8 weeks 12 weeks
Bioglass®45S5 57(±15)a 52(±18)a
Biosilicate®vítreo 66(±5)a 53(±4)a
Biosilicate 1F 44(±4)a 56(±8)a
Biosilicate 2F 48(±7)a 56(±6)a
BIC is expressed as percentage of the implant surface in direct 
contact with the mineralized bone matrix in cortical and medullary 
area. Parentheses numbers represent the standard deviation. 
Number of samples of each tested biomaterial in each period 
of time (n=8). Different letters in columns indicate statistically 
significant difference (ANOVA and Tukey’s post hoc test).
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Na2O.CaOSiO2 system composition may enhance bone 
tissue formation in an osteogenic cell culture system. 
Granito et al. (14) suggest that Biosilicate® exerts 
more osteogenic activity when compared to Bioglass® 
under subjective histopathological analysis, with no 
significant differences between these two materials 
when maximal load, energy absorption, and structural 
stiffness are analyzed. Roriz et al. (8) found similar 
results for Biosilicate® and Biogran® in alveolar ridge 
reconstruction, demonstrating an excellent response of 
the bioactive glass ceramics. It is important to stress that 
in vitro conditions are different from the in vivo situation, 
due to the impossibility of simulating homeostasis in 
a complex situation. In the study by Roriz et al. (8), 
Biosilicate®  presented more favorable results in both 
situations (in vitro and in vivo).
Previous studies have demonstrated that glass 
crystallization diminishes its bioactivity level (16) 
and some even suggested that crystallization might 
convert bioactive glasses into bioinert materials 
(17). Nevertheless, our results do not support this 
hypothesis. Xynos et al. (18) and Loty et al. (19) 
affirm that the total crystallization of Biosilicate® 
may alter some important properties of the material 
and consequently modify environment pH, turning it 
alkaline, which is favorable to osteoblast differentiation 
and function. The crystallization may even alter 
material properties like dissolution index, which might 
interfere on bone formation and be use to improve 
its biological properties. The different crystallization 
processes between Biosilicate®vítreo, Biosilicate 
1F and Biosilicate 2F may have interfered with 
bone formation. Despite the identical composition 
of Biosilicate 1F and 2F (crystalline) compared to 
Biosilicate®vítreo, the materials might present different 
dissolution capacity, kinetics and osseointegration. As 
previously mentioned, a very well domain on kinetic 
crystallization, nucleation, and growth allowed to obtain 
two glass ceramics fully crystallized: first showing only 
one crystalline phase containing 1Na2O.2CaO.3SiO2 
and P2O5 in solid solution (named F1), and the 
second having two crystalline phases containing 
1Na2O.2CaO.3SiO2 and a calcium phosphate phase 
(named F2). Unfortunately, the phosphate phase was 
not identified until now using x-ray diffraction due to 
its very low phosphate concentration (less than 1.8%). 
However, it was possible to observe the phosphate phase 
on FTIR spectra machine using diffuse reflectance (3).
The results showed that, regardless of the 
chemical composition, all evaluated implants were 
biocompatible, as demonstrated by their capacity for 
osseointegration, which was calculated as the percentage 
of new mineralized bone tissue formed in close contact 
with the implant surface. The chemical composition was 
important as a determinant of residual glass solubility 
and hence stability in the biological environment. The 
regular appearance of the Biosilicate® implants in 
all micrographs suggests that all tested compositions 
were stable in the biological environment. The tested 
Biosilicate® formulation was therefore considered 
suitable for implant use. The absence of inflammatory 
cells or multinucleated cells after 8 and 12 weeks 
demonstrated the applicability of all tested materials 
favoring BIC. Vogel et al. (20) showed that the presence 
of multinucleated cells diminishes bone union to 
the surface of the implant. In addition, the absence 
of macrophage activity decreases the possibility of 
dissolution of glass-based materials, which might create 
an acidic pH on local tissue environment (7). 
In conclusion, the results of the present study 
indicate that all tested materials are biocompatible and 
are suitable to be used in clinical dentistry.
RESUMO
O objetivo deste estudo foi investigar histologicamente e 
histomorfometricamente a resposta óssea a três diferentes fases 
cristalinas do Biosilicato®, comparando-os aos implantes de 
Bioglass®45S5 utilizados como controles. Implantes de cerâmicas 
de Biosilicato® e implantes de Bioglass®45S5 foram inseridos 
bilateralmente em fêmures de coelho e avaliações histológicas 
realizadas após 8 e 12 semanas. As avaliações histológicas não 
revelaram inflamação persistente ou reação de corpo estranho 
nos sítios de implantação dos biovidros. A formação de tecido 
ósseo pôde ser observada em maior quantidade na porção cortical, 
com tecido conjuntivo sendo observado em íntimo contato 
com as superfícies dos implantes apenas na porção medular. 
O tecido conjuntivo apresentou células com forma alongada 
e fibras de colágeno localizado paralelamente à superfície do 
implante. A porção cortical (após 8 semanas) foi a única área que 
demonstrou diferença significante entre os materiais estudados, 
com o Biosilicato 1F e o Biosilicato 2F demonstrando maior 
formação de tecido ósseo em contato com a superfície quando 
compardos aos implantes de Bioglass®45S5 e Biosilicato®vítreo 
(p=0,02). As outras áreas estudadas nos diferentes períodos não 
foram consideradas estatisticamente significantes (p>0,05). 
Pode-se concluir que todos os materiais testados foram 
considerados biocompatíveis, com formação óssea na superfície 
e comportamento em ambiente biológico satisfatório.
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